Upper Respiratory Tract Disorders – Pipeline Review, H2 2012

Upper Respiratory Tract Disorders – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Upper Respiratory Tract Disorders - Pipeline Review, H2 2012', provides an overview of the Upper Respiratory Tract Disorders therapeutic pipeline. This report provides information on the therapeutic development for Upper Respiratory Tract Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Upper Respiratory Tract Disorders. 'Upper Respiratory Tract Disorders - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Upper Respiratory Tract Disorders.
- A review of the Upper Respiratory Tract Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Upper Respiratory Tract Disorders pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Upper Respiratory Tract Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Upper Respiratory Tract Disorders pipeline depth and focus of Upper Respiratory Tract Disorders therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Upper Respiratory Tract Disorders Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Upper Respiratory Tract Disorders 10
Upper Respiratory Tract Disorders Therapeutics under Development by Companies 12
Upper Respiratory Tract Disorders Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Pre-Clinical Stage Products 18
Comparative Analysis 18
Upper Respiratory Tract Disorders Therapeutics – Products under Development by Companies 19
Upper Respiratory Tract Disorders Therapeutics – Products under Investigation by Universities/Institutes 21
Companies Involved in Upper Respiratory Tract Disorders Therapeutics Development 22
Alcon, Inc. 22
GlaxoSmithKline plc 23
Merck & Co., Inc. 24
Novartis Vaccines and Diagnostics, Inc. 25
OPKO Health, Inc. 26
Collegium Pharmaceutical, Inc. 27
Ahn-Gook Pharmaceutical Co., Ltd. 28
Verona Pharma Plc 29
Maywufa Company Limited 30
Lipocine Inc. 31
Afferent Pharmaceuticals, Inc. 32
AUS Bio Limited 33
Upper Respiratory Tract Disorders – Therapeutics Assessment 34
Assessment by Monotherapy Products 34
Assessment by Combination Products 35
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
Rolapitant - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
SB705498 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
SCH 900978 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
VRP-700 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
AF-219 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
PHN081 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Azithromycin - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
AG PPC709 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
AG1321001SY - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
AG NDT802 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
V501 + Menactra + Adacel - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Budesonide - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
BPZE1 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
COL-112 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
COL-131 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Epinephrine - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
FP01 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
AL53817 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Prednisone - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
GSK2339345 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Acellular Pertussis Vaccine + Tetanus-Diphtheria Booster Vaccine - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
MD 990 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Upper Respiratory Tract Disorders Therapeutics – Drug Profile Updates 63
Upper Respiratory Tract Disorders Therapeutics – Discontinued Products 67
Upper Respiratory Tract Disorders Therapeutics - Dormant Products 68
Upper Respiratory Tract Disorders – Product Development Milestones 69
Featured News & Press Releases 69
Jun 22, 2012: Sanofi Pasteur’s Hexaxim Receives Positive Opinion From European Medicines Agency 69
May 21, 2012: Cerecor Initiates CLIN01-002-A Phase II Study 70
Apr 11, 2012: Cerecor Announces Clearance Of IND For FP01 70
Nov 10, 2011: Ampio Announces Positive Results On Ampion Trial For Relief Of Nasal Inflammation 70
Sep 07, 2011: Verona Pharma Announces Results From Clinical Trial Of VRP700 71
Apr 11, 2011: Arbor Pharmaceuticals Acquires Erythromycin Products From Abbott Laboratories 72
Oct 27, 2010: Verona Pharma Initiates Clinical Trial Of VRP700 For Chronic Cough 72
Jun 28, 2010: Verona Pharma Seeks Regulatory Approval For Cough Trial 73
Feb 05, 2009: PhytoHealth Completes Patient Enrollment In Phase II Clinical Trial Of PHN081 (PDC-748), An Antitussive New Drug Candidate 73
Appendix 74
Methodology 74
Coverage 74
Secondary Research 74
Primary Research 74
Expert Panel Validation 74
Contact Us 75
Disclaimer 75

List of Tables
Number of Products Under Development for Upper Respiratory Tract Disorders, H2 2012 10
Products under Development for Upper Respiratory Tract Disorders – Comparative Analysis, H2 2012 11
Number of Products under Development by Companies, H2 2012 13
Number of Products under Investigation by Universities/Institutes, H2 2012 14
Comparative Analysis by Late Stage Development, H2 2012 15
Comparative Analysis by Mid Clinical Stage Development, H2 2012 16
Comparative Analysis by Early Clinical Stage Development, H2 2012 17
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 18
Products under Development by Companies, H2 2012 19
Products under Development by Companies, H2 2012 (Contd..1) 20
Products under Investigation by Universities/Institutes, H2 2012 21
Alcon, Inc., H2 2012 22
GlaxoSmithKline plc, H2 2012 23
Merck & Co., Inc., H2 2012 24
Novartis Vaccines and Diagnostics, Inc., H2 2012 25
OPKO Health, Inc., H2 2012 26
Collegium Pharmaceutical, Inc., H2 2012 27
Ahn-Gook Pharmaceutical Co., Ltd., H2 2012 28
Verona Pharma Plc, H2 2012 29
Maywufa Company Limited, H2 2012 30
Lipocine Inc., H2 2012 31
Afferent Pharmaceuticals, Inc., H2 2012 32
AUS Bio Limited, H2 2012 33
Assessment by Monotherapy Products, H2 2012 34
Assessment by Combination Products, H2 2012 35
Assessment by Stage and Route of Administration, H2 2012 37
Assessment by Stage and Molecule Type, H2 2012 39
Upper Respiratory Tract Disorders Therapeutics – Drug Profile Updates 63
Upper Respiratory Tract Disorders Therapeutics – Discontinued Products 67
Upper Respiratory Tract Disorders Therapeutics – Dormant Products 68

List of Figures
Number of Products under Development for Upper Respiratory Tract Disorders, H2 2012 10
Products under Development for Upper Respiratory Tract Disorders – Comparative Analysis, H2 2012 11
Products under Development by Companies, H2 2012 12
Products under Investigation by Universities/Institutes, H2 2012 14
Late Stage Products, H2 2012 15
Mid Clinical Stage Products, H2 2012 16
Early Clinical Stage Products, H2 2012 17
Pre-Clinical Stage Products, H2 2012 18
Assessment by Monotherapy Products, H2 2012 34
Assessment by Combination Products, H2 2012 35
Assessment by Route of Administration, H2 2012 36
Assessment by Stage and Route of Administration, H2 2012 37
Assessment by Molecule Type, H2 2012 38
Assessment by Stage and Molecule Type, H2 2012 39